公开(公告)号：US12295362B2

公开(公告)日：2025-05-13

申请号：US17592105

申请日：2022-02-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Muneeswara Babu Medi ,  Zhuojin Xu ,  Jung S. Lee ,  Yajin Ni ,  Mark W. Leonard

IPC: A01N1/125 ,  A61K40/11 ,  A61K40/31 ,  A61K40/42 ,  C12N5/0783

Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

公开(公告)号：US11896617B2

公开(公告)日：2024-02-13

申请号：US16857573

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles Pertel ,  Barbra Johnson Sasu ,  Mark W. Leonard

IPC: C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.